8 - 4 - 3

CASE D0051 NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
AUG 0 7 2003
TECH CENTER 1600/2900

IN RE APPLICATION OF

CHEN ET AL.

APPLICATION NO: 09/993,180

FILED: NOVEMBER 14, 2001

FOR: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN SERPIN
SECRETED FROM LYMPHOID CELLS LSI-01

MAIL STOP: DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of $180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289
Date: August 1, 2003

CASE D0051 NP

OIPE JC6T
AUG 0 1 2003
PATENT & TRADEMARK OFFICE

RECEIVED AUG 0 7 2003 TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CHEN ET AL.

APPLICATION NO: 09/993,180

FILED: NOVEMBER 14, 2001

FOR: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN SERPIN
SECRETED FROM LYMPHOID CELLS LSI-01

MAIL STOP: DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

09993180

08/06/2003 SSESHE1 00000131 193880
01 FC:1806   180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289

Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: August 1, 2003

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0051 NP
APPLICATION NO.
09/993,180
APPLICANT
CHEN ET AL.
FILING DATE
NOVEMBER 14, 2001

RECEIVED AUG 0 7 2003 TECH CENTER 1600/2900

Group

OIPE JC87 AUG 0 1 2003 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	US2003/0036156	2/20/03	Baker, et al.			
	AB	US2003/0036143	2/20/03	Baker, et al.			
	AC	US2003/0036162	2/20/03	Baker, et al.			
	AD	US2003/0036157	2/20/03	Baker, et al.			
	AE	US2003/0027272	2/6/03	Baker, et al.			
	AF	US2003/0032102	2/13/03	Baker, et al.			
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
	AM						☐	☐
	AN						☐	☐
	AO						☐	☐
	AP						☐	☐
	AQ						☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	
	AS	
	AT	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.